Antiretroviral (ARV) Drug Resistance in the Developing World.

Antiretroviral (ARV) Drug Resistance in the Developing World. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antiretroviral (ARV) Drug Resistance in the Developing World. Abstract Text:

M Maglione,M Geotz,Z Wang,G Wagner,L Hilton,J Carter,C Tringale,S Newberry,P Shekelle,Paul Shekelle,Margaret Maglione,Matthew Bidwell Geotz,Glenn Wagner,Zhen Wang,Lara Hilton,Jason Carter,Susan Chen,Carlo Tringle,Walter Mojica,Synde Newberry,Paul Shekelle,Margaret Maglione,Matthew Bidwell Geotz,Glenn Wagner,Zhen Wang,Lara Hilton,Jason Carter,Susan Chen,Carlo Tringle,Walter Mojica,Synde Newberry,

OBJECTIVES: To describe the overall prevalence of ARV resistance in the developing world, focusing on: (1) treatment naïve populations, (2) the resistance consequences of prevention of mother to child transmission (pMTCT) drug regimens, and (3) the relationship of medication adherence to resistance. DATA SOURCES: We searched PubMed(R), EMBASE, the Cochrane Controlled Clinical Trials Register Database, and the Cochrane Database of Reviews of Effectiveness (DARE). Additional sources of evidence included the Stanford University HIV Drug Resistance Database; reports of WATCH: Worldwide Analysis of Resistance Transmission over Time of Chronically and Acute Infected HIV-1 infected persons; a recent unpublished pMTCT overview; and various conference proceedings. Studies that did not report original research, that reported data already reported in another article, and case studies of fewer than 20 individuals were excluded. Of 1,122 titles identified, 117 journal articles and presentations were included. REVIEW METHODS: We abstracted data on geographic region, number of participants, subject demographics, HIV viral clade, medications taken (if any), years of data collection, how people were selected for resistance testing, and how and when resistance was assessed. Because of study heterogeneity, pooling was not possible; thus, the data are summarized qualitatively. Differences by region, population group, and HIV viral clade are described. RESULTS: The patterns of ARV resistance among treatment naïve populations worldwide appear to reflect geographic trends in use of ARV medications. A worldwide surveillance program (WATCH) found the rate of resistance (to any drug) among treatment naïve individuals was 5.5 percent in Africa, 7.4 percent in East Asia, 5.7 percent in Southeast Asia, and 6.4 percent in Latin America, lower than in North America (11.4 percent) and Europe (10.6 percent). Resistance data on HIV clades other than A, B, C, and D were too scarce to permit reliable conclusions. We also identified very few studies designed to assess the effect of health services delivery factors or medication adherence on the development of resistance in patients in developing countries. Evidence provided by longitudinal analyses suggests that, among women taking intrapartum single dose nevirapine (SD-NVP) to prevent mother-to-child transmission of HIV, both the overall prevalence of NNRTI resistance as well as the frequency of mutant virus in the overall viral population decreases with time since SD-NVP prophylaxis was received. CONCLUSIONS: In future resistance studies, rare HIV clades should be over-sampled in order to provide statistically meaningful data. Resistance surveillance programs should be maintained throughout the developing world, and data should be reported and analyzed in a consistent and timely manner. Where resources permit, studies of adherence in developing regions should conduct resistance testing.

Antiretroviral (ARV) Drug Resistance in the Developing World. Publishing Authors By Initials

M Maglione,M Geotz,Z Wang,G Wagner,L Hilton,J Carter,C Tringale,S Newberry,P Shekelle,P Shekelle,M Maglione,MB Geotz,G Wagner,Z Wang,L Hilton,J Carter,S Chen,C Tringle,W Mojica,S Newberry,P Shekelle,M Maglione,MB Geotz,G Wagner,Z Wang,L Hilton,J Carter,S Chen,C Tringle,W Mojica,S Newberry,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Antiretroviral (ARV) Drug Resistance in the Developing World. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Evidence report/technology assessment

VOLUME:

Page Numbers: 1-74

Journal Abbreviation:

ISSN: 1530-4396

DAY: 19

MONTH: Sep

YEAR: 2007

Antiretroviral (ARV) Drug Resistance in the Developing World. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101082681

Antiretroviral (ARV) Drug Resistance in the Developing World. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Antiretroviral (ARV) Drug Resistance in the Developing World. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Antiretroviral (ARV) Drug Resistance in the Developing World.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Evid Rep Technol Assess (Full

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antiretroviral ARV Drug Resistance in the Developing World Related Publications

• Antiretroviral (ARV) Drug Resistance in the Developing World.
• Delivery of genomic medicine for common chronic adult diseases: a systematic review.
• Evidence for improving palliative care at the end of life: a systematic review.
• Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians.
• Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set.
• Invited commentary: Implementation of health information technology: an important but challenging field of inquiry.
• Quality indicators for the care of hearing loss in vulnerable elders.
• Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians.
• Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline.
• Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis.
• Systematic review: the evidence that publishing patient care performance data improves quality of care.